PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Tumor-infiltrating myeloid cells such as myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) form an important component of the hypoxic tumor microenvironment. Here, we investigated the influence of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective ligands (PD-1 ligand 1 [PD-L1], PD-L2, CD80, and CD86) on MDSCs. We demonstrate that MDSCs at the tumor site show a differential expression of PD-L1 as compared with MDSCs from peripheral lymphoid organ (spleen). Hypoxia caused a rapid, dramatic, and selective up-regulation of PD-L1 on splenic MDSCs in tumor-bearing mice. This was not limited to MDSCs, as hypoxia also significantly increased the expression of PD-L1 on macrophages, dendritic cells, and tumor cells. Furthermore, PD-L1 up-regulation under hypoxia was dependent on hypoxia-inducible factor-1α (HIF-1α) but not HIF-2α. Chromatin immunoprecipitation and luciferase reporter assay revealed direct binding of HIF-1α to a transcriptionally active hypoxia-response element (HRE) in the PD-L1 proximal promoter. Blockade of PD-L1 under hypoxia enhanced MDSC-mediated T cell activation and was accompanied by the down-regulation of MDSCs IL-6 and IL-10. Finally, neutralizing antibodies against IL-10 under hypoxia significantly abrogated the suppressive activity of MDSCs. Simultaneous blockade of PD-L1 along with inhibition of HIF-1α may thus represent a novel approach for cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Figure 4. Blockade of PD-L1 under hypoxia down-regulates MDSC IL-6 and IL-10 and enhances T cell proliferation and function. MDSCs isolated from spleens of B16-F10 tumor-bearing mice were pretreated for 30 min on ice with 5 µg/ml control antibody (IgG) or antibody against PD-L1 (PDL1 Block) and co-cultured with splenocytes under normoxia and hypoxia for 72 h. (A and B) Effect of MDSC on proliferation of splenocytes stimulated with (A) anti-CD3/CD28 coated beads or (B) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured in triplicates by [3H]thymidine incorporation and expressed as counts per minute (CPM). (C and D) MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (C) CD3+CD8+ IFN-γ+ and (D) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (**, P < 0.005; ***, P < 0.0005). Three separate experiments (in triplicates) with the same results were performed. Error bars indicate SD. (E) SYBR-GREEN RT-qPCR was performed to evaluate the mRNA expression levels of Ldha, Car-9, Arg-1, Nos2, Ncf-1, and Cybb-1. (F) Arginase enzymatic activity measured in MDSCs under indicated conditions. (G) After 72 h of MDSC co-culture with splenocytes, supernatants were collected and assayed for nitrites. Data represents three independent experiments with SD. (H) SYBR Green RT-qPCR was performed for expression levels of IL6, IL10, Il12p70, and Tgfb1 under the indicated conditions. IL-6, IL-10, IL-12p70, and TGF-β1 cytokine production and secretion was detected by (I and J) intracellular FACS staining (isotype control is gray-shaded histogram) and (K) ELISA, respectively. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005; ***, P < 0.0005). The experiment was performed in triplicates and repeated three times with the same results. Error bars indicate SD. (L–O) MDSCs isolated from spleens of B16-F10 tumor-bearing mice were co-cultured with splenocytes under normoxia and hypoxia for 72 h in the presence of either 10 µg/ml control antibody (IgG), anti–mouse IL-6 Functional Grade Purified neutralizing antibody (IL-6 Block) or anti–mouse IL-10 Functional Grade Purified neutralizing antibody (IL-10 Block). Effect of MDSCs on proliferation of splenocytes stimulated with (L) anti-CD3/CD28–coated beads or (M) TRP-2(180–88) peptide under the indicated conditions. Cell proliferation was measured as indicated above. MDSCs were cultured with splenocytes from B16-F10 mice stimulated with anti-CD3/CD28. Intracellular IFN-γ production was evaluated by flow cytometry by gating on (N) CD3+CD8+ IFN-γ+ and (O) CD3+CD4+ IFN-γ+ populations. Statistically significant differences (indicated by asterisks) are shown (*, P < 0.05; **, P < 0.005). Two separate experiments (in triplicates) with the same results were performed. Error bars indicate SD.](https://figures.cochat.ai/paper-figures/2ba8a156b22c410c8802e99a6f19ff08/pd-l1-is-a-novel-direct-target-of-hif-1-and-its-blockade-under-hypoxia-enhanced-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, HIF-1α, but not HIF-2α, directly upregulates the expression of PD-L1 in macrophages, dendritic cells and bone marrow derived macrophages (BMDMs), by binding HREs within the PD-L1 promoter (Fig. 2C) [68–70].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [68]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As seen for the other cancer axes, the HIF-α dependency of PD-L1 is tumor-type dependent, with PD-L1 expression primarily HIF-1α driven in HIF-1α-dominant cancers (such as CT26 colon carcinoma and 4T1 breast carcinoma models) and HIF-2α-driven in HIF-2α-dominant cancers (ccRCC) [81, 83].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to regulating components of the innate immune response, the HIFs have been linked to modulation of the adaptive immune response through upregulation of both co-inhibitory (eg. PD-L1 and CTLA4) and co-stimulatory receptors (eg. 4–1BB, OX40) on activated T cells [80, 81].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent data indicate that hypoxia is also able to upregulate expression of PD-L1 in malignant cells via HIF-1α and HIF-2α (17).”
From Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting HIF-1α in immunotherapy is a relatively new concept, for which proof of principle has been amply demonstrated by others (12, 23, 27).”
From Targeting HIF-1α abrogates PD-L1–mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues (2022) · cites this paper as [12]
Experimental — accuracy not yet measured
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A large body of preclinical and clinical data indicates that antibody blockade of immune checkpoints can significantly enhance antitumor immunity (Pardoll, 2012; West et al., 2013).”
BackgroundSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“, 2012) and its ligand, PD-L1 (Brahmer et al., 2012), was shown to result in durable tumor regression and prolonged stabilization of disease in patients with advanced cancers.”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“MDSCs are a heterogeneous group of relatively immature myeloid cells and several studies have described mechanisms of MDSCmediated immune suppression (Gabrilovich et al., 2012).”
BackgroundSelf-citationGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 1×
“PD-1, a cell surface glycoprotein with a structure similar to cytotoxic T lymphocyte antigen 4 (CTLA-4), belongs to the B7 family of co-stimulatory/co-inhibitory molecules and plays a key part in immune regulation (Greenwald et al., 2005).”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645 · cited 3×
“It is important to underline that our results are in complete agreement with previous findings by Youn et al. (2008), indicating that normoxic blockade of PD-L1 did not eliminate suppressive activity of MDSCs.”
BackgroundMethodResultInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · cited 12×
“2 I) and DCs (CD11c+; Fig.”
BackgroundResultInfluentialPD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J.-I., Cheng, P., Cho, H.-I., Celis, E., Quiceno, D. G., Padhya, T., et al. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100587 · Cited by 1,173 · cited 6×
“As shown previously by Corzo et al. (2010), we observed higher levels of Arg-1 gene expression (Fig.”
BackgroundInfluentialOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993 · cited 1×
“2014 Vol. 211 No. 5 781-790 www.jem.org/cgi/doi/10.1084/jem.20131916 781 Brief Definit ive Report Hypoxia is a common feature of solid tumors (Semenza, 2011).”
BackgroundInfluential
Cited by
Items 501–600 of 1,009
Pellegrino, B., Musolino, A., Llop‐Guevara, A., Serra, V., Silva, P. D., Hlavata, Z., Sangiolo, D., Willard-Gallo, K. E., & Solinas, C. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.10.010 · Cited by 81
“Nonetheless, PARPi-induced hypoxia has been shown to selectively upregulate the expression of PD-L1 by protumor myeloid-derived suppressor cells (MDSCs) [112] and by HIF-related mechanisms [91].”
BackgroundCresswell, G. M., Wang, B., Kischuk, E. M., Broman, M. M., Alfar, R. A., Vickman, R. E., Dimitrov, D. S., Kularatne, S. A., Sundaram, C. P., Singhal, S. K., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1414 · Cited by 85
“Because PD-L1 expression has been implicated in the immunosuppressive properties of MDSCs and TAMs (24, 25), particularly under hypoxia (25), we next undertook to investigate whether PD-L1 might correlate with FRb expression.”
BackgroundMethodRadiotherapy: An immune response modifier for immuno-oncology
Martino, M. D., Daviaud, C., & Vanpouille‐Box, C. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101474 · Cited by 88
Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
Lee, J., Han, Y., Wang, W., Jo, H., Kim, H., Kim, S., Yang, K., Kim, S., Dhanasekaran, D. N., & Song, Y. S. (2021) · Biomolecules · doi:10.3390/biom11081107 · Cited by 95
“In addition, high levels of HIF1α are associated with immune suppression and PD-L1 overexpression by binding on the promoter of PD-L1, suggesting that a hypoxic environment may lead to a pro-tumorigenic immune landscape as well as decreased tumor cell apoptosis [35].”
BackgroundCpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials
Zhang, Z., Kuo, J. C., Yao, S., Zhang, C., Khan, H., & Lee, R. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010073 · Cited by 79
The Role of Myeloid-Derived Suppressor Cells in Immune Ontogeny
Gantt, S., Gervassi, A., Jaspan, H., & Horton, H. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00387 · Cited by 76
MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs
Pyzer, A. R., Stroopinsky, D., Rosenblatt, J., Anastasiadou, E., Rajabi, H., Washington, A., Tagde, A., Chu, J.-H., Coll, M., Jiao, A. L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.163 · Cited by 76
Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer
Chen, R., Zhou, X., Liu, J., & Huang, G. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4208-8 · Cited by 77
“Moreover, hypoxia-inducible factor 1α (HIF1α) binds directly to the hypoxia-responsive element (HRE) in the proximal promoter of PD-L1 and upregulates PD-L1 expression [27].”
BackgroundJia, D., Li, X., Bocci, F., Tripathi, S., Deng, Y., Jolly, M. K., Onuchic, J. N., & Levine, H. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050725 · Cited by 84
Hu, Z., Chen, J., Zhou, S., Yang, N., Duan, S., Zhang, Z., Su, J., He, J., Zhang, Z., Lü, X., et al. (2017) · Theranostics · doi:10.7150/thno.16236 · Cited by 75
“On the contrary, decreased numbers of peripheral blood, tumor, and bone marrow MDSCs are associated with a reduction in the tumor volume in cancer patients following surgery or molecular targeted therapy [28].”
BackgroundMolecular Regulation of Bone Metastasis Pathogenesis
Wu, M., Li, C.-J., Yiang, G., Cheng, Y., Tsai, A. P., Hou, Y.-T., Ho, Y.-C., Hou, M., & Chu, P. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000489184 · Cited by 79
Lorenzo-Sanz, L., & Muñoz, P. (2019) · Cancer Microenvironment · doi:10.1007/s12307-019-00232-2 · Cited by 86
Maenhout, S. K., Thielemans, K., & Aerts, J. L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.956579 · Cited by 74
“PD-L1 is upregulated on these MDSCs under the influence of hypoxia and blockade of PD-L1 under hypoxic conditions abrogated the MDSC-mediated T-cell suppression by modulating MDSC cytokine production.(41) In different tumor models it has been shown that CD80 expression is upregulated on tumor-derived MDSCs.”
BackgroundTCR-engineered T cells to treat tumors: Seeing but not touching?
Debets, R., Donnadieu, E., Chouaïb, S., & Coukos, G. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.002 · Cited by 80
Xing, Y., Mi, C., Wang, Z., Zhang, Z. H., Li, M. Y., Zuo, H. X., Wang, J. Y., Jin, X., & Ma, J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.004 · Cited by 78
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
Personeni, N., Pressiani, T., & Rimassa, L. (2019) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s168953 · Cited by 82
“Any TeAe 470 (99) 357 (75) 472 (99) 316 (67) Any treatment-related TEAE 447 (94) 270 (57) 452 (95) 231 (49) Hypertension 201 (42) 111 (23) 144 (30) 68 (14) Diarrhea 184 (39) 20 (4) 220 (46) 20 (4) Decreased appetite 162 (34) 22 (5) 127 (27) 6 (1) Decreased weight 147 (31) 36 (8) 106 (22) 14 (3) Fatigue 141 (30) 18 (4)…”
The role of hypoxia on prostate cancer progression and metastasis
Mohamed, O. A. A., Tesen, H. S., Hany, M., Sherif, A., Abdelwahab, M. M., & Elnaggar, M. H. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08251-5 · Cited by 88
“PDL-1ligand interacts with the PD-1 receptor on T cells to inactivate T cells and inhibit their function [29].”
BackgroundZhang, B., Liu, J., Mo, Y., Zhang, K., Huang, B., & Shang, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476904 · Cited by 111
Immune regulation of canine tumour and macrophage PD‐L1 expression
Hartley, G. P., Faulhaber, E. A., Caldwell, A. B., Coy, J., Kurihara, J. N., Guth, A., Regan, D. P., & DOW, S. W. (2016) · Veterinary and Comparative Oncology · doi:10.1111/vco.12197 · Cited by 84
Kakizaki, A., Fujimura, T., Furudate, S., Kambayashi, Y., Yamauchi, T., Yagita∥, H., & Aiba, S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1047584 · Cited by 83
Semaan, A., Dietrich, D., Bergheim, D., Dietrich, J., Kalff, J. C., Branchi, V., Matthaei, H., Kristiansen, G., Fischer, H., & Goltz, D. (2016) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-016-2051-5 · Cited by 73
Metabolic heterogeneity and adaptability in brain tumors
Badr, C. E., Silver, D. J., Siebzehnrübl, F. A., & Deleyrolle, L. P. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03569-w · Cited by 77
“Re-educating” Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma
Liu, K. X., & Joshi, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01947 · Cited by 84
Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy
Feng, Y., Tang, Q., Wang, B., Yang, Q., Zhang, Y., Lei, L., & Li, S. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03005-2 · Cited by 83
“Hypoxia significantly upregulates the abundance of PD-L1, causing an increase in PDL1 and CTLA4 mRNA expression mediated by HIF-1α binding to the hypoxia response element (HRE) of PD-L1 [50].”
Hypoxic Microenvironment and Metastatic Bone Disease
Hiraga, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113523 · Cited by 82
“showed that hypoxia upregulates the expression of programmed death-ligand 1 (PD-L1) in MDSCs and increases MDSC-mediated T cell tolerance [60].”
BackgroundThe Engagement Between MDSCs and Metastases: Partners in Crime
Trovato, R., Canè, S., Petrova, V., Sartoris, S., Ugel, S., & Sanctis, F. D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00165 · Cited by 79
Ruan, W.-S., Feng, M.-X., Xu, J. M., Xu, Y., Song, C., Lin, L.-Y., Li, L., & Lu, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01299 · Cited by 79
“Co-culture of PMN-MDSC and T Cells PMN-MDSC suppression of T cell activation was assayed as described before (15).”
BackgroundMethodLiu, L., Yao, Z., Wang, S., Xie, T., Wu, G., Zhang, H., Zhang, P., Wu, Y., Yuan, H., & Sun, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00392 · Cited by 75
Monocyte-neutrophil entanglement in glioblastoma
Friedmann‐Morvinski, D., & Hambardzumyan, D. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163451 · Cited by 78
Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy
Zeng, Q., Liu, M., Wang, Z., Zhou, R., & Ai, K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02366-y · Cited by 94
“PD-L1 blockade of MDSCs leads to an increase in activated T cells [72, 73].”
Yaghi, L., Poras, I., Simoes, R. T., Donadi, E. A., Tost, J., Daunay, A., de Almeida, B. S., Carosella, E. D., & Moreau, P. (2016) · Oncotarget · doi:10.18632/oncotarget.11628 · Cited by 71
“A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/ PD-L1, and HLA-G.”
BackgroundInfluentialOstrand‐Rosenberg, S., Horn, L. A., & Ciavattone, N. G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00215 · Cited by 77
Tumor microenvironment-related dendritic cell deficiency: a target to enhance tumor immunotherapy
Zhu, S., Yang, N., Wu, J., Wang, X., Wang, W., Liu, Y.-J., & Chen, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104980 · Cited by 71
Role of purines in regulation of metabolic reprogramming
Tang, Z., Ye, W., Chen, H., Kuang, X., Guo, J., Xiang, M., Peng, C., Chen, X., & Liu, H. (2019) · Purinergic Signalling · doi:10.1007/s11302-019-09676-z · Cited by 79
The B7x Immune Checkpoint Pathway: From Discovery to Clinical Trial
John, P., Yao, W., Liu, W., Du, M., Guan, F., & Zang, X. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.008 · Cited by 73
“Stimuli such as hypoxia signaling through HIF-1a have been shown to induce PD-L1 [57] as well as B7x [52] in tumor cells in vitro, but why tumors preferentially express one or the other in vivo is not clear.”
BackgroundGuillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 78
Yuan, C.-S., Deng, Z., Qin, D., Mu, Y., Chen, X., & Liu, Y. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.02.030 · Cited by 72
Metabolic Plasticity of Neutrophils: Relevance to Pathogen Responses and Cancer
Rogers, T., & DeBerardinis, R. J. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.04.007 · Cited by 75
Metabolic regulation of the cancer-immunity cycle
Patterson, L. F. S., & Vardhana, S. A. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.09.002 · Cited by 87
Tumor-Mediated Neutrophil Polarization and Therapeutic Implications
Raftopoulou, S., Valadez-Cosmes, P., Mihalič, Z. N., Schicho, R., & Kargl, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063218 · Cited by 75
Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy
Zhou, Y., Yuan, J. T., Xu, K., Li, S., & Liu, Y. (2024) · ACS Nano · doi:10.1021/acsnano.3c11260 · Cited by 78
Cancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment
Raaijmakers, K., Adema, G. J., Bussink, J., & Ansems, M. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03251-0 · Cited by 88
The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
Chu, G. J., van Zandwijk, N., & Rasko, J. E. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01366 · Cited by 70
Zuo, H. X., Jin, Y., Wang, Z., Li, M. Y., Zhang, Z. H., Wang, J. Y., Xing, Y., Ri, M., Jin, C. H., Xu, G. H., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112835 · Cited by 70
The PD-1:PD-L1 axis in Inflammatory Arthritis
Canavan, M., Floudas, A., Veale, D. J., & Fearon, U. (2021) · BMC Rheumatology · doi:10.1186/s41927-020-00171-2 · Cited by 82
López-Codony, V., & Tavassoli, M. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101017 · Cited by 77
Roles of tumor-associated neutrophils in tumor metastasis and its clinical applications
Yan, M., Zheng, M., Niu, R., Yang, X., Tian, S., Fan, L., Li, Y., & Zhang, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.938289 · Cited by 83
“Some molecules are hypothesized to be linked to the antitumor response, such as CD177 and CD101, or the protumor response, such as lectin-like oxidized low-density lipoprotein (LOX1), CD117, and programmed death-ligand 1 (PD-L1) (Noman et al., 2014; Condamine et al., 2016; Cheng et al., 2018; Evrard et al., 2018; Zhou…”
BackgroundLi, L., & Tian, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114504 · Cited by 79
Targeting hypoxia at the forefront of anticancer immune responses
Noman, M. Z., & Chouaib, S. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954463 · Cited by 70
“More importantly, hypoxia upregulated IL-6 and IL-10 levels in MDSCs was significantly attenuated after PD-L1 blockade.(7) Our data seem to be a more general mechanism, as blockade of tumor microenvironment-induced PD-L1 on myeloid dendritic cells has been shown to decrease myeloid dendritic cell-mediated immunosuppre…”
BackgroundResultInfluentialSelf-citationHypoxia-inducible factor 1 in autoimmune diseases
Deng, W., Feng, X., Li, X., Wang, D., & Sun, L. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.04.001 · Cited by 75
Nunes‐Xavier, C. E., Angulo, J. C., Pulido, R., & Lopez, J. I. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0866-8 · Cited by 80
Okuma, A., Hanyu, A., Watanabe, S., & Hara, E. (2017) · Nature Communications · doi:10.1038/s41467-017-02281-x · Cited by 69
Porta, C., Sica, A., & Riboldi, E. (2018) · The FEBS Journal · doi:10.1111/febs.14288 · Cited by 69
Chyuan, I., Chu, C., & Hsu, P. (2021) · Cancers · doi:10.3390/cancers13061188 · Cited by 71
“Furthermore, hypoxia in the TME can induce the expression of hypoxia-inducible factor 1-alpha and promote both Treg generation and maintenance and PD-L1 expression in MDSCs, thereby exerting potent immunosuppressive effects on tumor-specific effector T cells [72].”
BackgroundCastella, B., Foglietta, M., Sciancalepore, P., Rigoni, M. M., Coscia, M., Griggio, V., Vitale, C., Ferracini, R., Saraci, E., Omedè, P., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1047580 · Cited by 78
“The BM microenvironment is highly hypoxic in MM,(25) and it has recently been shown that hypoxia induces PD-L1 upregulation in splenic MDSC from tumorbearing mice, but not in MDSC from peripheral lymphoid organs not infiltrated by tumor cells.(26) Interestingly, Myklebust et al.”
BackgroundAguirre, L. E., Guzman, M. E., Lopes, G., & Hurley, J. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0195 · Cited by 68
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 75
“Furthermore, hypoxia facilitates recruitment of MDSCs and enhances their immunosuppressive function (111).”
BackgroundMetabolic heterogeneity in cancer: An overview and therapeutic implications
Yu, T., Gao, W., & Liu, Y. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188421 · Cited by 77
HIF-1α Metabolic Pathways in Human Cancer
Elzakra, N., & Kim, Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51652-9_17 · Cited by 77
Han, C., Ye, S., Hu, C., Shen, L., Qin, Q., Bai, Y., Yang, S., Bai, C., Zang, A., Jiao, S., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684867 · Cited by 76
“In addition, Noman found that inhibiting angiogenesis induced hypoxia in tumor tissue, which in turn upregulated PD-L1 expression on macrophages, dendritic cells, and tumor cells (33).”
BackgroundHypoxia as a Modulator of Inflammation and Immune Response in Cancer
Castillo‐Rodríguez, R. A., Trejo‐Solís, C., Cabrera‐Cano, A., Gómez‐Manzo, S., & Dávila‐Borja, V. M. (2022) · Cancers · doi:10.3390/cancers14092291 · Cited by 81
Tanaka, T., Kutomi, G., Kajiwara, T., Kukita, K., Kochin, V., Kanaseki, T., Tsukahara, T., Hirohashi, Y., Torigoe, T., Okamoto, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14960 · Cited by 70
Modulating glioma-mediated myeloid-derived suppressor cell development with sulforaphane
Kumar, R., de Mooij, T., Peterson, T. E., Kaptzan, T., Johnson, A. J., Daniels, D. J., & Parney, I. F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179012 · Cited by 74
Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma
Pang, L., Khan, F., Heimberger, A. B., & Chen, P. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.04.010 · Cited by 67
Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity
Ortmann, B. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000154 · Cited by 67
Immune checkpoint blockade for the treatment of human hepatocellular carcinoma
Nishida, N., & Kudo, M. (2018) · Hepatology Research · doi:10.1111/hepr.13191 · Cited by 74
Hypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers
Zhang, H., Cao, K., Xiang, J., Zhang, M., Zhu, M., & Xi, Q. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216345 · Cited by 72
Advanced Hepatocellular Cancer: the Current State of Future Research
Connell, L. C., Harding, J. J., & Abou‐Alfa, G. K. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0415-3 · Cited by 67
The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era
Spyrou, N., Vallianou, N. G., Kadillari, J., & Dalamaga, Μ. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.008 · Cited by 72
Heterogeneous Myeloid Cells in Tumors
Dou, A., & Fang, J. (2021) · Cancers · doi:10.3390/cancers13153772 · Cited by 78
Chung, Y. M., Khan, P. P., Wang, H., Tsai, W.-B., Qiao, Y., Yu, B., Larrick, J. W., & Hu, M. C. ‐. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002772 · Cited by 69
Role of regulation of PD-1 and PD-L1 expression in sepsis
Zhang, T., Yu-Jing, L., & Ma, T. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1029438 · Cited by 91
“Both HIF-1a and HIF-2a have been shown to physically interact with the hypoxia response element (HRE) in the promoter region of PD-L1 (83, 114).”
BackgroundRegulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer
He, Z., Zhang, C., Zhao, Y., He, S., Li, Y., Shi, B., Hu, J., Qi, R., & Hua, B. (2023) · Discover Oncology · doi:10.1007/s12672-023-00793-1 · Cited by 76
“HIF-1α can induce programmed death ligand-1 (PD-L1) expression on the surface of MDSCs by binding to the programmed death factor-1 (PD-1) on the T-cell surface, which causes T-cell immune dysfunction and induces T-cell depletion and apoptosis [35, 36].”
BackgroundMao, F.-Y., Zhao, Y., Lv, Y.-P., Teng, Y., Kong, H., Liu, Y., Wu, X., Hao, C.-J., Chen, W., Duan, M., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0803-7 · Cited by 71
Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting
Yu, Y.-R., & Ho, P. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13293 · Cited by 69
Shklovskaya, E., & Rizos, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197139 · Cited by 73
“Signaling via HIF-1α [38], β-catenin [173], AXL tyrosine kinase [174,175], YAP [73,74] and ZEB1 pathways [79,80] variably contributes to augmented PD-L1 expression in de-differentiated tumors.”
BackgroundCD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma
Lewinsky, H., Gunes, E. G., David, K., Radomir, L., Kramer, M. P., Pellegrino, B., Shahor, M. P., Chen, J., He, T.-F., Mansour, A. G., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141683 · Cited by 79
“Previously, HIF1α has been shown to have a role both in differentiation and PD-L1 expression on MDSCs (28).”
BackgroundMonocyte programming by cancer therapy
Patysheva, M. R., Frolova, A. A., Larionova, I., Afanas’ev, S. G., Тарасова, А. С., Чердынцева, Н. В., & Kzhyshkowska, J. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.994319 · Cited by 75
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors
Semenza, G. L. (2021) · Physiology · doi:10.1152/physiol.00034.2020 · Cited by 64
Targeted Anti-Mitochondrial Therapy: The Future of Oncology
Taghizadeh‐Hesary, F., Behnam, B., Akbari, H., & Bahadori, M. (2022) · Genes · doi:10.3390/genes13101728 · Cited by 64
“Moreover, in response to targeted therapies, cancer cells can circumvent the blocked pathway through many different mechanisms [111], including (1) restoration of the targeted molecules (e.g., BCR-ABL kinase reactivation in imatinib therapy of chronic myelogenous leukemia) [112], (2) activation of upstream and downstr…”
BackgroundInfluentialT‐cell exhaustion in CAR‐T ‐cell therapy and strategies to overcome it
Yin, X., He, L., & Guo, Z. (2023) · Immunology · doi:10.1111/imm.13642 · Cited by 74
“Hypoxia in the TME can upregulate PDL-1 on MDSCs and increase the ability of MDSCs to suppress TILs [80].”
BackgroundHypoxia: syndicating triple negative breast cancer against various therapeutic regimens
Srivastava, N., Usmani, S. S., Subbarayan, R., Saini, R., & Pandey, P. K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1199105 · Cited by 72
Brodská, B., Otevřelová, P., Šálek, C., Fuchs, O., Gašová, Z., & Kuželová, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112823 · Cited by 71
“PD-L1 surface expression can be induced both by cell-extrinsic mechanisms, such as proinflammatory cytokines [46–48] or hypoxia [49,50], and by cell-intrinsic activation of some signaling pathways [51,52].”
BackgroundTemozolomide promotes immune escape of GBM cells via upregulating PD-L1.
Wang, S., Yao, F., Lu, X., Li, Q., Su, Z., Lee, J.-H., Wang, C., & Du, L. (2019) · PubMed · Cited by 62
Hammami, A., Charpentier, T., Smans, M., & Stäger, S. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004938 · Cited by 64
Association of PD-L1 and HIF-1α Coexpression with Poor Prognosis in Hepatocellular Carcinoma
Dai, X., Pi, G., Yang, S., Chen, G. Y., Liu, L., & Dong, H. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.02.014 · Cited by 70
“Strikingly, hypoxia can significantly increase the PD-L1 expression on myeloid-derived suppressor cells, macrophages, dendritic cells, and tumor cells, and further acquired resistance to CTL-mediated lysis is in a certain manner dependent on HIF-1α [24,25].”
BackgroundResultCancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion
Hilmi, M., Nicolle, R., Bousquet, C., & Neuzillet, C. (2020) · Cancers · doi:10.3390/cancers12102969 · Cited by 69
“First, HIF-1α upregulates the expression of PD-L1 by MDSCs, macrophages, DCs, and tumor cells, thereby promoting T cell inactivation through the PD-1/PD-L1 axis [89].”
BackgroundHypoxia, a key factor in the immune microenvironment
Hu, J., Li, X., Yang, L., & Li, H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113068 · Cited by 68
Revitalizing T cells: breakthroughs and challenges in overcoming T cell exhaustion
Wu, Y., Wu, Y., Gao, Z., Yu, W., Zhang, L., & Zhou, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02327-3 · Cited by 89
Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy
Hong, B.-J., Kim, J., Jeong, H., Bok, S., Kim, Y.-E., & Ahn, G.-O. (2016) · Radiation Oncology Journal · doi:10.3857/roj.2016.02012 · Cited by 63
“Furthermore, it is recently reported that the expression of programmed death-ligand 1 (PD-L1), the major inhibitory ligand towards cytotoxic T cells by binding to its cognate receptor PD-1 [9] is regulated by hypoxia-inducible factor-1 (HIF-1) [10], a master transcription factor well known to be stabilized in hypoxic…”
BackgroundRossi, S., Toschi, L., Castello, A., Grizzi, F., Mansi, L., & Lopci, E. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3802-5 · Cited by 69
Kaderbhaï, C., Tharin, Z., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11020201 · Cited by 69
Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK
Giles, A. J., Hao, S., Padget, M. R., Song, H., Zhang, W., Lynes, J. P., Sánchez, V., Liu, Y., Jung, J., Cao, X., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130688 · Cited by 63
“PD-L1 is upregulated by hypoxia and IFN-γ (32, 33), which are associated with advanced grade in meningioma (34).”
BackgroundInfluentialTargeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy
Wang, Y., Jia, A., Bi, Y., Wang, Y., Yang, Q., Cao, Y., Li, Y., & Liu, G. (2020) · Cancers · doi:10.3390/cancers12092626 · Cited by 68
“Pr gramm d death ligand-1 (PD-L1) on MDSCs induced by hypoxia-inducible factor 1-alpha (HIF-1α) promotes apoptosis of T cells by binding to programmed cell death-1 (PD-1) on the surface of T cells [36].”
BackgroundLamberti, G., Sisi, M., Andrini, E., Palladini, A., Giunchi, F., Lollini, P., Ardizzoni, A., & Gelsomino, F. (2020) · Cancers · doi:10.3390/cancers12113129 · Cited by 70
“HIF-1α directly binds the hypoxia-response element (HRE) in the CD274 proximal promoter, inducing PD-L1 expression in myeloid-derived suppressor cells (MDSCs) and tumor cells [43,118].”
BackgroundInfluentialLakshmanachetty, S., Cruz, J. C., Hoffmeyer, E., Cole, A. P., & Mitra, S. S. (2021) · Cells · doi:10.3390/cells10040893 · Cited by 69
“Although recent advances in immune checkpoint blockade (ICD) therapies such as anti-PD-1/PD-L1 and anti-CTLA4 have yielded promising results in melanoma and non-small lung cancer [3], glioma patients not only failed to respond in clinical trials but also developed resistance to ICB in a multitude of ways [4].”
BackgroundInfluentialHypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma
Xu, S., Tang, L., Liu, Z., Luo, C., & Cheng, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.731048 · Cited by 76
“Besides, HIF-1a could increase the expression of PD-L1 by binding to its hypoxia response elements (45).”
BackgroundHofer, F., Sario, G. D., Musiu, C., Sartoris, S., Sanctis, F. D., & Ugel, S. (2021) · Cells · doi:10.3390/cells10102700 · Cited by 69
“Moreover, tumour-associated hypoxia favours the upregulation of PD-L1 expression at the MDSC cell surface [104], and this suppresses T cell activation by binding to the immune checkpoint receptor programmed death 1 (PD-1).”
BackgroundImmunometabolism: Another Road to Sepsis and Its Therapeutic Targeting
Kumar, V. (2018) · Inflammation · doi:10.1007/s10753-018-0939-8 · Cited by 71
“For example, it controls the expression of PDL-1 on MDSCs and thus the apoptosis of PD-1 expressing antigen-specific CD8 Tcells [170, 171].”
Background
Metadata
- Authors
- Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S.
- Affiliations
- Inserm (FR)
- Istituto Oncologico Veneto (IT)
- Centre de Recherche Public de la Santé (LU)
- Institut Gustave Roussy (FR)
- University of Verona (IT)
- Unité Institut National de la Santé et de la Recherche Médicale U753, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2014-04-28
- Volume
- 211
- Issue
- 5
- Pages
- 781-790
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4010891
- OpenAlex
- W2149360266
- Semantic Scholar
- dad078dcb463c50f1571acb3306b01954a153c29
- Cited by
- 2,166
- References
- 24
- Citations by year
- 2026: 171 · 2025: 187 · 2024: 208 · 2023: 219 · 2022: 239 · 2021: 331 · 2020: 224 · 2019: 147 · 2018: 139 · 2017: 120 · 2016: 101 · 2015: 61 · 2014: 18
- FWCI
- 48.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-L1, HIF-1α, hypoxia, myeloid-derived suppressor cells, tumor microenvironment, immune checkpoint blockade, T cell activation, hypoxia response element, IL-10, interleukin-6, tumor-associated macrophages, cancer immunotherapy, CTLA-4, PD-1 ligands
- MeSH terms
- Animals, Diamines, Enzyme-Linked Immunosorbent Assay, Female, Flow Cytometry, Gene Expression Regulation, Luciferases, Lymphocyte Activation, Mice, Inbred C57BL, Organic Chemicals, Quinolines, T-Lymphocytes, Cell Hypoxia, Myeloid Cells, RNA Interference, Chromatin Immunoprecipitation, Mice, Hypoxia-Inducible Factor 1, alpha Subunit, Benzothiazoles, Tumor Microenvironment, Real-Time Polymerase Chain Reaction, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.